Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts

• Asıl Yazarlar: Mohammad-Reza Tamadon (Yazar), Jamileh Moghimi (Yazar), Hamed Rezaei (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Society of Diabetic Nephropathy Prevention, 2018-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Context: IgA nephropathy (IgAN) as an autoimmune disease is the most common cause of glomerulonephritis worldwide. Rituximab effectively depletes B cells and reduces serum levels of IgA1 antibodies. This paper aimed to review the potential benefit of rituximab used in clinical practice of IgAN patie...